Coronaviruses cause severe human viral diseases including SARS, MERS and COVID-19. Most recently SARS-CoV-2 virus (causing COVID-19) has led to a pandemic with no successful therapeutics. The SARS-CoV-2 infection relies on trimeric spike (S) proteins to facilitate virus entry into host cells by binding to ACE2 receptor on host cell membranes. Therefore, blocking this interaction with antibodies are promising agents against SARS-CoV-2. Here we describe using humanized llama antibody VHHs against SARS-CoV-2 that would overcome the limitations associated with polyclonal and monoclonal combination therapies. From two llama VHH libraries, unique humanized VHHs that bind to S protein and block the S/ACE2 interaction were identified. Furthermore, pairwise combination of VHHs showed synergistic blocking. Multi-specific antibodies with enhanced affinity and avidity, and improved S/ACE2 blocking are currently being developed using an approach that also fuses VHHs to Fc domains. Importantly, our current bi-specific antibody shows potent S/ACE2 blocking (KD - 0.25 nM, IC100 ∼ 36.7 nM, IC95 ∼ 12.2 nM, IC50 ∼ 1 nM) which is significantly better than individual monoclonal VHH-Fcs. Overall, this design would equip the VHH-Fcs multiple mechanisms of actions against SARS-CoV-2. Thus, we aim to contribute to the battle against COVID-19 by developing therapeutic antibodies as well as diagnostics.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284970PMC
http://dx.doi.org/10.1080/22221751.2020.1768806DOI Listing

Publication Analysis

Top Keywords

humanized llama
8
affinity avidity
8
s/ace2 blocking
8
blocking
5
sars-cov-2
5
development multi-specific
4
multi-specific humanized
4
antibodies
4
llama antibodies
4
antibodies blocking
4

Similar Publications

Article Synopsis
  • Despite progress in HIV treatment through antiretroviral therapy (ART), limitations like lifelong medication and viral resistance drive the need for new approaches.
  • Ibalizumab is currently the only approved CD4-specific antibody, and research into anti-CD4 nanobodies, particularly one called Nb457 from an alpaca, shows promise for better efficacy against HIV-1.
  • Nb457, especially in its engineered trimeric form, not only surpasses Ibalizumab in effectiveness but also demonstrates significant therapeutic benefits in mouse models, indicating potential for future clinical applications.
View Article and Find Full Text PDF

Identification and biophysical characterization of a novel domain-swapped camelid antibody specific for fentanyl.

J Biol Chem

August 2024

Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA; Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA. Electronic address:

Opioid use disorders (OUD) and overdoses are ever-evolving public health threats that continue to grow in incidence and prevalence in the United States and abroad. Current treatments consist of opioid receptor agonists and antagonists, which are safe and effective but still suffer from some limitations. Murine and humanized monoclonal antibodies (mAb) have emerged as an alternative and complementary strategy to reverse and prevent opioid-induced respiratory depression.

View Article and Find Full Text PDF

Immunoglobulin G-based monoclonal antibodies (mAbs) have been effective in treating various diseases, but their large molecular size can limit their penetration of tissue and efficacy in multifactorial diseases, necessitating the exploration of alternative forms. In this study, we constructed a phage display library comprising single-domain antibodies (sdAbs; or "VHHs"), known for their small size and remarkable stability, using a total of 1.6 × 10 lymphocytes collected from 20 different alpacas, resulting in approximately 7.

View Article and Find Full Text PDF
Article Synopsis
  • The ODYSSEY OUTCOMES trial showed that alirocumab, a monoclonal antibody, significantly reduced the risk of recurrent cardiovascular events and all-cause death compared to placebo, over more than 47,000 patient-years.
  • Alirocumab effectively lowered low-density lipoprotein cholesterol levels and had a safety profile similar to placebo, with only a slight increase in local injection site reactions (about 1.7%).
  • The drug was found to be safe for vulnerable groups, including the elderly and those with diabetes or previous health issues, and demonstrated consistent results over a period of at least 5 years.
View Article and Find Full Text PDF

Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.

Int J Mol Sci

February 2024

Dermatology Department, Hospital Universitario de la Princesa, Fundación de Investigación Biomédica de la Princesa, 28006 Madrid, Spain.

Mogamulizumab (MOG) is an antibody targeting the CCR4 receptor, authorized for relapsed or refractory peripheral T-cell (PTCL) and cutaneous T-cell lymphomas (CTCL). Its adoption in guidelines and endorsement by FDA and EMA established it as a systemic treatment, especially for advanced disease stages due to its comparatively lower toxicity. Clinical trials and real-world evidence have underscored its efficacy in advanced CTCLs, including mycosis fungoides and Sézary syndrome; PTCLs; and adult T-cell leukemia/lymphoma (ATLL), showcasing positive outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!